Search results
With new Enhertu data, an ADC could overtake chemo in breast cancer
BioPharma Dive via Yahoo Finance· 5 days agoLayman also didn’t take part in the trial, but is an investigator in a...The study hasn’t continued...
Cullinan Therapeutics announces success for zipalertinib as combo therapy
Clinical Trials Arena via Yahoo Finance· 3 days agoThe Phase I/II REZILIENT1 trial (...enrolled in the Phase IIb portion and 18 were evaluable. There...
Newswise Expert | Yuanyuan Zhang, UT Southwestern Medical Center
Newswise· 2 days agoYuanyuan Zhang, M.D., Ph.D., is an Assistant Professor of Radiation Oncology at UT Southwestern Medical Center specializing in treating lung cancer patients ...
'Outstanding' Results for Osimertinib: Stage III EGFR+ NSCLC
Medscape· 3 days agoResults from the LAURA trial will change practice once its label gets expanded, experts said at the...
ASCO 24: Data shows survival benefit with J&J’s subcutaneous Rybrevant
Clinical Trials Arena via Yahoo Finance· 5 days agoThe secondary efficacy endpoint data now have the field abuzz. While the objective response rate...
'Disturbing' surge in young cancers may be linked to gut health, say experts
Daily Express· 4 days agoUnhealthy lifestyles, an obesity epidemic and poor gut health are feared to be fuelling a...
Why US Drug Giant Bristol Myers Squibb Stock Trading Up On Monday - Bristol-Myers Squibb (NYSE:BMY)
Benzinga· 3 days agoAt...median follow-up of 9.4 months, Krazati demonstrated a statistically significant and clinically...
ASCO: Replacing chemotherapy with ADCs? AbbVie rebuilds next-gen assets after Rova-T flop
FierceBiotech· 2 days agoA new trend has emerged at this year’s American Society of Clinical Oncology conference: the...
Rural Patients With Melanoma Fare Worse Than Urban Dwellers
Medscape· 17 hours agoThe findings come from an analysis of Surveillance, Epidemiology, and End Results (SEER) data over...
'Outstanding' 5 Year PFS With Lorlatinib in ALK+ NSCLC
Medscape· 6 days agoFive-year follow-up data from the landmark CROWN trial shows significant progression-free survival in ALK+ NCSLC, but some experts question the use of crizotinib as the comparator drug.